-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Aprea Therapeutics, Inc. (NASDAQ:APRE) to Post Q1 2023 Earnings of ($0.10) Per Share, Wedbush Forecasts
Aprea Therapeutics, Inc. (NASDAQ:APRE) to Post Q1 2023 Earnings of ($0.10) Per Share, Wedbush Forecasts
Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating) – Research analysts at Wedbush boosted their Q1 2023 earnings per share estimates for shares of Aprea Therapeutics in a research note issued on Monday, August 15th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.10) per share for the quarter, up from their previous estimate of ($0.11). Wedbush has a "Outperform" rating and a $3.00 price target on the stock. The consensus estimate for Aprea Therapeutics' current full-year earnings is ($1.12) per share. Wedbush also issued estimates for Aprea Therapeutics' FY2023 earnings at ($0.45) EPS.
Get Aprea Therapeutics alerts:Aprea Therapeutics (NASDAQ:APRE – Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.02.
Aprea Therapeutics Stock Performance
Aprea Therapeutics stock opened at $0.89 on Thursday. The stock's 50 day moving average price is $0.93 and its 200 day moving average price is $1.31. Aprea Therapeutics has a one year low of $0.62 and a one year high of $5.67. The firm has a market capitalization of $20.84 million, a PE ratio of -0.16 and a beta of 0.63.Hedge Funds Weigh In On Aprea Therapeutics
A number of institutional investors have recently made changes to their positions in APRE. Jane Street Group LLC acquired a new stake in shares of Aprea Therapeutics during the 2nd quarter valued at approximately $54,000. PDT Partners LLC grew its stake in Aprea Therapeutics by 62.5% during the 4th quarter. PDT Partners LLC now owns 142,600 shares of the company's stock worth $409,000 after buying an additional 54,866 shares during the last quarter. Magnus Financial Group LLC bought a new stake in Aprea Therapeutics in the fourth quarter valued at $98,000. Gyon Technologies Capital Management LP acquired a new position in shares of Aprea Therapeutics during the first quarter valued at $38,000. Finally, Renaissance Technologies LLC grew its position in shares of Aprea Therapeutics by 5.7% during the first quarter. Renaissance Technologies LLC now owns 297,900 shares of the company's stock worth $554,000 after acquiring an additional 15,977 shares during the last quarter. 16.46% of the stock is owned by institutional investors and hedge funds.
Aprea Therapeutics Company Profile
(Get Rating)
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.
Recommended Stories
- Get a free copy of the StockNews.com research report on Aprea Therapeutics (APRE)
- If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
- Is Sanofi A Buy, Despite Recent Stumbles?
- Institutional Support For TJX Companies May Cap Gains
- Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
- BJ's Wholesale Club Pops, Will Costco Be Next?
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating) – Research analysts at Wedbush boosted their Q1 2023 earnings per share estimates for shares of Aprea Therapeutics in a research note issued on Monday, August 15th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.10) per share for the quarter, up from their previous estimate of ($0.11). Wedbush has a "Outperform" rating and a $3.00 price target on the stock. The consensus estimate for Aprea Therapeutics' current full-year earnings is ($1.12) per share. Wedbush also issued estimates for Aprea Therapeutics' FY2023 earnings at ($0.45) EPS.
Aprea治疗公司(纳斯达克:APRE-GET评级)--韦德布什的研究分析师在8月15日星期一发布的一份研究报告中上调了他们对Aprea治疗公司股票2023年第一季度每股收益的预期。韦德布什分析师R.Driscoll现在预测,该公司本季度每股收益将为0.10美元,高于此前预测的0.11美元。韦德布什对该股的评级为“跑赢大盘”,目标价为3.00美元。对Aprea治疗公司目前全年收益的普遍估计为每股1.12美元。韦德布什还发布了对Aprea治疗公司2023财年每股收益的估计为0.45美元。
Aprea Therapeutics (NASDAQ:APRE – Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.02.
Aprea治疗公司(纳斯达克:APRE-GET评级)最近一次发布季度收益报告是在5月16日(星期一)。该公司公布本季度每股收益(0.36美元),比普遍预期的(0.38美元)高出0.02美元。
Aprea Therapeutics Stock Performance
Aprea治疗公司股票表现
Hedge Funds Weigh In On Aprea Therapeutics
对冲基金对Aprea Treeutics的看法
A number of institutional investors have recently made changes to their positions in APRE. Jane Street Group LLC acquired a new stake in shares of Aprea Therapeutics during the 2nd quarter valued at approximately $54,000. PDT Partners LLC grew its stake in Aprea Therapeutics by 62.5% during the 4th quarter. PDT Partners LLC now owns 142,600 shares of the company's stock worth $409,000 after buying an additional 54,866 shares during the last quarter. Magnus Financial Group LLC bought a new stake in Aprea Therapeutics in the fourth quarter valued at $98,000. Gyon Technologies Capital Management LP acquired a new position in shares of Aprea Therapeutics during the first quarter valued at $38,000. Finally, Renaissance Technologies LLC grew its position in shares of Aprea Therapeutics by 5.7% during the first quarter. Renaissance Technologies LLC now owns 297,900 shares of the company's stock worth $554,000 after acquiring an additional 15,977 shares during the last quarter. 16.46% of the stock is owned by institutional investors and hedge funds.
一些机构投资者最近改变了他们在APRE的头寸。简街集团在第二季度收购了Aprea治疗公司的新股份,价值约为5.4万美元。第四季度,PDT Partners LLC在Aprea Treateutics的持股增加了62.5%。PDT Partners LLC在上个季度额外购买了54,866股后,现在拥有该公司14.26万股股票,价值40.9万美元。Magnus Financial Group LLC在第四季度购买了Aprea治疗公司的新股份,价值9.8万美元。Gyon Technologies Capital Management LP在第一季度收购了Aprea治疗公司的新股票,价值3.8万美元。最后,复兴技术有限责任公司在第一季度将其在Aprea治疗公司的股票头寸增加了5.7%。复兴科技有限责任公司在上个季度增持了15,977股后,现在持有该公司297,900股股票,价值554,000美元。16.46%的股票由机构投资者和对冲基金持有。
Aprea Therapeutics Company Profile
Aprea治疗公司简介
(Get Rating)
(获取评级)
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.
Aprea治疗公司是一家临床阶段的生物制药公司,专注于开发和商业化针对DNA损伤反应通路的新型癌症疗法。它的主要候选产品是ATRN-119,这是一种口服ATR抑制剂,正在进行1/2a期临床试验,用于治疗晚期实体肿瘤患者。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Aprea Therapeutics (APRE)
- If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
- Is Sanofi A Buy, Despite Recent Stumbles?
- Institutional Support For TJX Companies May Cap Gains
- Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
- BJ's Wholesale Club Pops, Will Costco Be Next?
- 免费获取StockNews.com关于Aprea治疗公司(APRE)的研究报告
- 如果你讨厌超速摄像头,那么你会喜欢Verra Mobility Stock
- 尽管赛诺菲最近跌跌撞撞,但它是买入的吗?
- 对TJX公司的机构支持可能限制涨幅
- 星巴克股票,品牌忠诚度足以成为购买理由吗
- BJ‘s批发俱乐部流行音乐,Costco会是下一个吗?
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Aprea治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Aprea治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧